Description. The mission of the Pediatric Neuro-Oncology Program at OHSU Doernbecher Children’s Hospital is to promote the well-being of children and adolescents with brain tumors …

Cohorts 1A and 1B (participants with newly diagnosed DMG prior to radiation therapy). New diagnosis of DMG with imaging and/or pathology consistent with a DMG, including spinal cord …

The RAS/RAF/MEK/ERK pathway is implicated in a number of adult cancers and NF1-associated tumors. Similarly, the majority of pediatric LGGs possess abnormal signaling through the …

INCLUSION CRITERIA. Key Inclusion Criteria: Age 0 to <18 years of age (Phase 1) Age ≥3 and ≤25 years of age (Efficacy Phase) Karnofsky ≥50 for patients >16 years of age and Lansky …

Linda Stork, MD Principal Investigator, Pediatric Hematologist/Oncologist. Dr. Linda Stork is Director of the OHSU Doernbecher Blood and Cancer Program and Division ...

The estimated incidence of primary CNS tumors in children and adolescents ≤ 19 years of age is 5.6 cases per 100,000 person years. As the most common CNS tumors in children and …

Please note, this study has closed to accrual and is no longer accepting patients. || Eligible patients will undergo focal radiation therapy after initial diagnosis as part of their standard of …

PRIMARY OBJECTIVES. The primary objective of this study is to estimate the rate of progression-free survival (PFS) at 6 months following everolimus therapy for symptomatic, …

Please note, this study has closed to accrual and is no longer accepting patients. || This study will include children and young adults (3-39 years of age) with newly diagnosed DIPG, recurrent …

PNOC002: Pilot Efficacy Study of vemurafenib, an oral inhibitor of BRAFV600E, in Children with Recurrent/Refractory BRAFV600E-mutant gliomas